Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Molecular and Clinical Analysis of Large B-Cell Lymphomas with MYC gene Involvement: Impact of the Co-Occurrence of TP53 Deletion

Francesca Bonello, Enrico Berrino, Mara Panero, Mattia Novo, Alessia Castellino, Federico Itri, Sara Erika Bellomo, Pio Manlio Mirko Frascione, Barbara Botto, Alberto Bragoni, Valentina Fabiola Ilenia Sangiorgio, Delia Rota-Scalabrini, Caterina Marchiò, Anna Sapino, Laura Casorzo, Umberto Vitolo

Blood (2024) 144 (Supplement 1): 6189.

https://doi.org/10.1182/blood-2024-208448

Published: 2024

Journal Articles

Survival of Hodgkin Lymphoma Patients Treated with Novel Immunotherapies after Autologous Stem Cell Transplantation Failure: A Retrospective Analysis of the Italian Lymphoma Foundation (FIL)

Maura Nicolosi, Valentina Bozzoli, Sabino Ciavarella, Cattina Federica, Gloria Margiotta Casaluci, Ombretta Annibali, Alessia Castellino, Francesco Rotondo, Luigi Petrucci, Federica Cocito, Sofya Kovalchuk, Erika Meli, Natalia Cenfra, Sara Bigliardi, Angelo Fama, Stefano Volpetti, Barbara Botto, Benedetto Bruno, Francesco Zaja

Blood (2023) 142 (Supplement 1): 6219.

https://doi.org/10.1182/blood-2023-187563

Published: 2023

Journal Articles

Copanlisib in Combination with Rituximab and Bendamustine for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: Results from the Phase II Multicenter Fil_Copa-Rb Trial from Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2023-184718

Published: 2023

Journal Articles

Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era

Yucai Wang, Melissa C. Larson, Alessia Castellino, Matthew J. Maurer, Andrew L. Feldman, Sergei Syrbu, Brian K. Link, Umar Farooq, David J. Inwards, Jonas Paludo, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 2429.

https://doi.org/10.1182/blood-2021-147538

Published: 2021

Journal Articles

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Melissa C Larson, MS, Cristine Allmer, BS, Susan L. Slager, PhD, Thomas M. Habermann, MD, Sunnia T Chen, BS, Hector R Villarraga, MD, Joerg Herrmann, MD, Gita Thanarajasingam, MD, Alessia Castellino, MD, Grzegorz Nowakowski, MD, David J Inwards, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2019) 134 (Supplement_1): 422.

https://doi.org/10.1182/blood-2019-127203

Published: 2019

Journal Articles

Lenalidomide in Combination with Standard R-CHOP Overcomes the Negative Prognostic Value of Peripheral Blood Absolute Lymphocyte/Monocyte Ratio at Diagnosis and during Treatment in Patients with Diffuse Large B-Cell Lymphoma

Alessia Castellino, MD, Levy D. Pederson, Kay M. Ristow, BS, Christina Stenzel, Betsy Laplant, MS, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Grzegorz S. Nowakowski, MD, Luis Porrata, MD

Blood (2018) 132 (Supplement 1): 4139.

https://doi.org/10.1182/blood-2018-99-114010

Published: 2018

Journal Articles

Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era

Alessia Castellino, MD, Melissa C. Larson, MS, Matthew J. Maurer, MS, Susan L. Slager, PhD, Cristine Allmer, BS, Jonathon B. Cohen, MD MS, Andrew L. Feldman, MD, Sergei Syrbu, MD PhD, Brian K. Link, MD, Umar Farooq, MD, David J Inwards, MD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD

Blood (2018) 132 (Supplement 1): 4140.

https://doi.org/10.1182/blood-2018-99-119595

Published: 2018

Journal Articles

Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018

Alessia Castellino, MD, Jose Pulido, PhD, Patrick Johnston, Kay M. Ristow, BS, Nabila Nora Bennani, MD, David J Inwards, MD, William R. Macon, MD, Ivana N Micallef, MD, Rebecca L King, MD, Diva Salomao, MD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Grzegorz Nowakowski, MD

Blood (2018) 132 (Supplement 1): 574.

https://doi.org/10.1182/blood-2018-99-113826

Published: 2018

Journal Articles

High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Prophyling: A Combined Analysis from Two Phase 2 Trials

Alessia Castellino, MD, Annalisa Chiappella, MD, Betsy Laplant, MS, Levy D. Pederson, Giorgio Inghirami, MD, Gianluca Gaidano, MD PhD, William R Macon, MD, Alessandra Tucci, Rebecca L King, MD, Angela Giovanna Congiu, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Umberto Vitolo, Grzegorz S. Nowakowski, MD

Blood (2018) 132 (Supplement 1): 2962.

https://doi.org/10.1182/blood-2018-99-119495

Published: 2018

Journal Articles

Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohystochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP

Chiara Ciochetto, Maria Stella Scalzo, Barbara Botto, Alessia Castellino, Annalisa Chiappella, MD, Mattia Novo, Maura Nicolosi, Elisa Santambrogio, Federica Cavallo, MD, Paola Ghione, Andrea Evangelista, MSc, Giovannino Ciccone, MD PhD, Roberto Chiarle, MD, Domenico Novero, MD, Umberto Vitolo, MD

Blood (2016) 128 (22): 5305.

https://doi.org/10.1182/blood.V128.22.5305.5305

Published: 2016

Journal Articles

De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC)

Barbara Botto, Alessia Castellino, Annalisa Chiappella, Mattia Novo, Luigi Zattera, Federica Cavallo, Paola Ghione, Andrea Evangelista, Chiara Ciochetto, Giovannino Ciccone, Maria Stella Scalzo, Roberto Chiarle, Domenico Novero, Umberto Vitolo

Blood (2015) 126 (23): 2650.

https://doi.org/10.1182/blood.V126.23.2650.2650

Published: 2015

Journal Articles

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study

Blood (2015) 126 (23): 3946.

https://doi.org/10.1182/blood.V126.23.3946.3946

Published: 2015

Journal Articles

The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP

Barbara Botto, Domenico Novero, Annalisa Chiappella, Mattia Novo, Alessia Castellino, Chiara Ciochetto, Giovanni Cametti, Andrea Evangelista, Roberto Freilone, Paola Ghione, Marco Ladetto, Paola Riccomagno, Federico Vittone, Giovannino Ciccone, Umberto Vitolo

Blood (2014) 124 (21): 2964.

https://doi.org/10.1182/blood.V124.21.2964.2964

Published: 2014

Journal Articles

Relapsed Or Refractory Aggressive Non Hodgkin B-Cell Lymphomas Treated With Lenalidomide With/Without Rituximab Or Steroids: A Single Center Restrospective Study

Alessia Castellino, Annalisa Chiappella, Paola Ghione, Manuela Ceccarelli, Giulia Benevolo, MD, Barbara Botto, Daniele Caracciolo, Chiara Ciochetto, Maura Nicolosi, Lorella Orsucci, Clara Pecoraro, Patrizia Pregno, Paola Riccomagno, Manuela Zanni, Marco Ladetto, Umberto Vitolo, MD

Blood (2013) 122 (21): 5119.

https://doi.org/10.1182/blood.V122.21.5119.5119

Published: 2013

Journal Articles

Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

Blood (2013) 122 (21): 850.

https://doi.org/10.1182/blood.V122.21.850.850

Published: 2013

Journal Articles

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 903.

https://doi.org/10.1182/blood.V120.21.903.903

Published: 2012

Journal Articles

Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

Blood (2011) 118 (21): 1606.

https://doi.org/10.1182/blood.V118.21.1606.1606

Published: 2011

NARROW

Molecular and Clinical Analysis of Large B-Cell Lymphomas with MYC gene Involvement: Impact of the Co-Occurrence of TP53 Deletion

Survival of Hodgkin Lymphoma Patients Treated with Novel Immunotherapies after Autologous Stem Cell Transplantation Failure: A Retrospective Analysis of the Italian Lymphoma Foundation (FIL)

Copanlisib in Combination with Rituximab and Bendamustine for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: Results from the Phase II Multicenter Fil_Copa-Rb Trial from Fondazione Italiana Linfomi (FIL)

Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Lenalidomide in Combination with Standard R-CHOP Overcomes the Negative Prognostic Value of Peripheral Blood Absolute Lymphocyte/Monocyte Ratio at Diagnosis and during Treatment in Patients with Diffuse Large B-Cell Lymphoma

Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era

Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018

High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Prophyling: A Combined Analysis from Two Phase 2 Trials

Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohystochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP

De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC)

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study

The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP

Relapsed Or Refractory Aggressive Non Hodgkin B-Cell Lymphomas Treated With Lenalidomide With/Without Rituximab Or Steroids: A Single Center Restrospective Study

Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only